"We’re in this with you, to help you get the care you need, safely. Vanderbilt Health has restarted surgeries, procedures and clinic visits that were paused or delayed. Safety is our top priority, with measures that follow – and in some cases exceed – local, state and CDC public health recommendations. Everyone wears a mask – patients, visitors, doctors, nurses and staff. We’re sanitizing rooms between each patient, and cleaning public spaces frequently throughout the day. We’re checking everyone for fever and symptoms before they enter our facilities. We’ve spaced chairs in waiting areas, limited the number who can ride elevators at once and made other changes so we can keep a safe (6 feet) physical distance."

During the past decade, Vanderbilt University Medical Center - Digestive Disease Center conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vanderbilt University Medical Center - Digestive Disease Center" #1 sponsor was "Gilead Sciences" with 3 trials, followed by "Pfizer" with 2 trials sponsored, "Calliditas Therapeutics Suisse SA" with 1 trials sponsored, "Conatus Pharmaceuticals Inc." with 1 trials sponsored and "CymaBay Therapeutics, Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vanderbilt University Medical Center - Digestive Disease Center" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Vanderbilt University Medical Center - Digestive Disease Center" are "Nonalcoholic Steatohepatitis" (3 trials), "Primary Biliary Cholangitis" (2 trials), "Primary Sclerosing Cholangitis" (2 trials), "Compensated Cirrhosis" (1 trials) and "Eosinophilic Esophagitis" (1 trials). Many other conditions were trialed in "Vanderbilt University Medical Center - Digestive Disease Center" in a lesser frequency.

Most popular intervention types in "Vanderbilt University Medical Center - Digestive Disease Center" are "Drug" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Placebo to match SEL 18 mg" (2 trials), "Placebo to match SEL 6 mg" (2 trials), "SEL" (2 trials) and "Cilofexor" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vanderbilt University Medical Center - Digestive Disease Center" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Vanderbilt University Medical Center - Digestive Disease Center". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Vanderbilt University Medical Center - Digestive Disease Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Vanderbilt University Medical Center - Digestive Disease Center, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".